• Sign Up
  • |
  • Sign In Sign Out
  • |
  • Make us your home
  • |
  • RSS
1 2
1 15
1 4
1 9
1 13
1 14
IPO
1 25
1 5018
SME
1 5018
  • MAY JOIN RACE FOR SHELL'S EUROPEAN REFINERIES: SOURCES
  • SENSEX, NIFTY UP 1% EACH FOR THE WEEK
  • CNX MIDCAP INDEX UP 1%, BSE SMALLCAP INDEX UP 1.6%
  • METAL INDEX UP 3.7%, AUTO INDEX UP 2.3%, FMCG UP 1.5%
  • INDEX GAINERS: SUZLON UP 9.3%, TATA STEEL UP 6.3%, SAIL UP 5.3%
  • RIL SPOKESPERSON TO NDTV: 'REVIEWS CANNOT ASSURE TRANSACTIONS'
  • RIL SPOKESPERSON: 'WE ARE REVIEWING A NUMBER OF GLOBAL OPPORTUNITIES'
  • ESSAR-SHELL IN EXCLUSIVE NEGOTIATIONS TILL NOV 30 TO BUY 3 SHELL REFINERIES
  • APPROACHED SHELL FOR BUYOUTS BEFORE ESSAR'S EXCLUSIVE TALKS BEGUN
  • JSW ENERGY ALSO IN RACE FOR ANDREW YULE'S DPSC STAKE: NW
  • CESC, SREI INFRA IN RACE FOR ANDREW YULE'S DPSC STAKE: NW
  • GAMMON INFRA BAGS NHAI PROJECT WORTH RS.850 CRORES
  • NET PROFIT AT RS.48.2 CR VS RS.12 CR; SALES UP 55% AT RS.849 CR (YOY)
  • PROFIT UP 55% AT RS.143.50 CR; NET SALES UP 22.5% AT RS.2234.20 (YOY)
  • IMPORTING SUGAR BEING REVIEWED; NEED FOR ECONOMIC PRICING OF SUGAR
  • IN DISCUSSIONS WITH FARMERS TO COME AT PRICE COMFORTABLE FOR BOTH SIDES
  • TOO EARLY TO TALK OF DENA BANK MERGER WITH ANOTHER PSU BANK: NW
  • KEEPS OVERNIGHT LENDING RATE UNCHANGED AT 0.1%
  • STILL SEE DOWNSIDE RISK FOR THE ECONOMY
  • AIM TO CONVERT NON USERS TO USERS WITH THE HELP OF ROAMING TARIFF CUTS
  • PREFER TO REMAIN AGGRESSIVE WITHOUT GETTING INTO A PRICE WAR
  • MURTAZA KHORAKIWALA TO NDTV: CANNOT COMMENT ON SUB JUDICE MATTER
  • WOCKHARDT TO PAY BACK ALL SECURED, UNSECURED LOANS IN 5 YRS AS PER CDR
  • DBS TOP BRASS MET HABIL KHORAKIWALA TO DISCUSS WAYS OF SETTLEMENT: SRCS
  • EYEING TO SETTLE PAYMENT DEFAULT CASE OUT OF COURT: SOURCES
  • ALERT: ROAMING CONTRIBUTES 15% OF BHARTI REVENUES
  • ROAMING CALLS ON OTHER NETWORKS AT 80 PAISE/MINUTE
  • ROAMING CALLS ON OWN NETWORK AT 60 PAISE/MIN
  • SWAP TO REDUCE OVERALL FINANCE CHARGES FOR THE COMPANY: CFO
  • COMPLETES SWAP OF $875MN FOREX CONVERTIBLE BONDS
Updated: 27/07/2008 | 02:51 PM IST
IT firms help pharma cos maintain profits
Press Trust of India
Sunday, July 27, 2008 (New Delhi)
Comments:
Read (0)

With global pharma companies leveraging IT to cut costs, Indian technology firms such as TCS, Satyam, Patni and Cognizant are now stepping up presence in life science space.

"Increasing costs of R&D, coupled with low productivity and poor bottom lines, have forced major pharma companies worldwide to outsource part of their data management activities to low-cost countries, thereby saving costs and time in the process," TCS Vice President and Global Head - Life Sciences and Healthcare ISU - Debashis Ghosh said.

Indian IT companies have been helping life sciences organisations with services ranging from application development, maintenance, testing and upgrade to global roll out and implementation, he added.

The country's largest software exporter TCS earns about 5.3 per cent of its revenue from the life science processes.

According to a research firm Life Science Insights (LSI), worldwide IT spending for the life science sector would reach 38.9 billion dollar by the end of 2008, driven by the need to tackle regulatory burdens and costly clinical trials, and by life sciences companies leveraging IT to enable personalized medicine.

"With data growth fast outpacing the growth in the infrastructure capabilities of life science companies, it has become a necessity to outsource key activities related to storing, accessing, securing, and managing of data.

"This, coupled with the regulatory compliance, is driving the IT intervention amongst the life science companies," Cognizant Life Sciences Practice Leader J Sairamkumar said.

Pharmaceutical companies are expanding Post-Market Drug Safety Initiatives to prevent adverse reactions. This is because of heightened public awareness of drug safety, greater regulatory scrutiny, a number of recent drug withdrawals and black box warnings, industry experts said.

Out of the several processes, the adverse event case processing is becoming a fast growing service stream.

Adverse event reporting relates to tracking changes in health or side effects that occurs in a person who participates in a clinical trial while he is receiving treatment or within specified period.

It is a computerised information database designed to support the FDA's post-marketing safety surveillance program for all approved drug and therapeutic biologic products.

Patni which is a major player in the life science process outsourcing space said adverse event case processing is a growing service stream.

"This is a fairly young but rapidly growing segment of Knowledge Process Outsourcing (KPO) where apart from technologists, we are inducting doctors, pharmacists and even nurses who bring understanding of medicare processes and help in extending services," Patni Senior Vice-President and Head Sanjiv Kapur said.

Adverse Event case processing outsourcing is complex and is part of KPO. As per various market estimates, KPO is expected to grow to 17 billion dollar by end of 2010 and will employ about 2,50,000 professionals, he added.

Another IT major Satyam Computer Services had recently formed an alliance with a Westborough-based life science KPO company Sciformix Corporation to deliver data management services in Pharmacovigilance.

Both the companies would collaborate to enable pharmaceutical and biotechnology companies to better monitor the safety of the products they market by offering services across the safety management spectrum, ranging from case intake to international regulatory reporting.

With drug safety being listed as a front and center concern for 2008 for life sciences organisations by Health Industry Insights (January 2008), many more outsourcing deals are likely to come to the Indian IT firms.

Comments:
Read (0)
Comments
 
Market Watch
         
Graphs
Stocks

                                Moremore
Stock Dashboard
Trading Calls
Rupal Saraogi
Rupal Saraogi
2.09% status
Current: Rs 1755.5
Simi Bhaumik
Simi Bhaumik
2.43% status
Current: Rs 2335.75
Stock Recos
The investors should remain invested in the stock
The investors can book partial profit and hold the remaining stock with a stoploss of closing below Rs 105
Buy or Sell
Today's Analyst: Neera Jain
Query : Sukhendu, an investor from Mumbai, has 500 Wockhardt at Rs 184/share.